Tofenacin: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
== Tofenacin == | |||
[[File:Tofenacin.svg|thumb|right|Chemical structure of Tofenacin]] | |||
Tofenacin | |||
'''Tofenacin''' is a [[tricyclic antidepressant]] (TCA) that was developed in the 1960s. It is primarily used in the treatment of [[depression]] and has been studied for its effects on various neurotransmitter systems in the brain. | |||
Tofenacin is used in the treatment of | |||
== | === Pharmacology === | ||
Tofenacin works by inhibiting the reuptake of [[norepinephrine]] and [[serotonin]], two key neurotransmitters involved in mood regulation. This action increases the concentration of these neurotransmitters in the synaptic cleft, thereby enhancing neurotransmission and improving mood in patients with depression. | |||
== | === Chemical Properties === | ||
Tofenacin is | Tofenacin is a member of the tricyclic antidepressant class, characterized by its three-ring chemical structure. The chemical structure of Tofenacin is depicted in the image to the right. This structure is crucial for its ability to interact with neurotransmitter transporters in the brain. | ||
== | === Clinical Use === | ||
Tofenacin is prescribed for the treatment of major depressive disorder. It is typically administered orally and dosage is adjusted based on the patient's response and tolerance to the medication. Like other TCAs, Tofenacin may take several weeks to exhibit its full therapeutic effects. | |||
[[ | === Side Effects === | ||
[[ | Common side effects of Tofenacin include [[dry mouth]], [[constipation]], [[urinary retention]], and [[blurred vision]]. These effects are due to its anticholinergic properties. Patients may also experience [[drowsiness]], [[weight gain]], and [[orthostatic hypotension]]. | ||
[[ | |||
=== Mechanism of Action === | |||
Tofenacin's primary mechanism of action is the inhibition of the reuptake of norepinephrine and serotonin. By blocking the transporters responsible for the reuptake of these neurotransmitters, Tofenacin increases their availability in the synaptic cleft, which is thought to contribute to its antidepressant effects. | |||
=== History === | |||
Tofenacin was developed in the 1960s during a period of extensive research into tricyclic antidepressants. It was one of several compounds synthesized to improve the efficacy and reduce the side effects associated with earlier antidepressants. | |||
== Related Pages == | |||
* [[Tricyclic antidepressant]] | |||
* [[Depression (mood disorder)]] | |||
* [[Norepinephrine]] | |||
* [[Serotonin]] | |||
[[Category:Tricyclic antidepressants]] | |||
[[Category:Antidepressants]] | |||
Latest revision as of 03:57, 13 February 2025
Tofenacin[edit]

Tofenacin is a tricyclic antidepressant (TCA) that was developed in the 1960s. It is primarily used in the treatment of depression and has been studied for its effects on various neurotransmitter systems in the brain.
Pharmacology[edit]
Tofenacin works by inhibiting the reuptake of norepinephrine and serotonin, two key neurotransmitters involved in mood regulation. This action increases the concentration of these neurotransmitters in the synaptic cleft, thereby enhancing neurotransmission and improving mood in patients with depression.
Chemical Properties[edit]
Tofenacin is a member of the tricyclic antidepressant class, characterized by its three-ring chemical structure. The chemical structure of Tofenacin is depicted in the image to the right. This structure is crucial for its ability to interact with neurotransmitter transporters in the brain.
Clinical Use[edit]
Tofenacin is prescribed for the treatment of major depressive disorder. It is typically administered orally and dosage is adjusted based on the patient's response and tolerance to the medication. Like other TCAs, Tofenacin may take several weeks to exhibit its full therapeutic effects.
Side Effects[edit]
Common side effects of Tofenacin include dry mouth, constipation, urinary retention, and blurred vision. These effects are due to its anticholinergic properties. Patients may also experience drowsiness, weight gain, and orthostatic hypotension.
Mechanism of Action[edit]
Tofenacin's primary mechanism of action is the inhibition of the reuptake of norepinephrine and serotonin. By blocking the transporters responsible for the reuptake of these neurotransmitters, Tofenacin increases their availability in the synaptic cleft, which is thought to contribute to its antidepressant effects.
History[edit]
Tofenacin was developed in the 1960s during a period of extensive research into tricyclic antidepressants. It was one of several compounds synthesized to improve the efficacy and reduce the side effects associated with earlier antidepressants.